Department of Medical Oncology, CHU Henri Mondor, Créteil, France.
Zoledronic acid has been the standard of care for the prevention of skeletal-related events in patients with bone metastases from prostate cancer for the past 10 years. However, its potent antitumor activity has been questioned. We report the occurrence of a complete clinical and biological response to zoledronic acid in a patient with bone metastases from castrate-resistant prostate cancer.
Written by:
Pouessel D, Culine S. Are you the author?
Reference: Anticancer Drugs. 2011 Sep 20. Epub ahead of print.
PubMed Abstract
PMID: 21934600
UroToday.com Prostate Cancer Section